Therein lies one of the most pragmatic reasons to address health inequity—inaction is financially unsustainable. However, ...

Advances in genetic cell modifications are performed routinely in research laboratories, but clinical translation requires ...

HIBISCUS phase 2 data evaluating the safety profile and efficacy of etavopivat in adult and adolescent patients with sickle ...

Novo Nordisk today announced the presentation of 13 abstracts at the upcoming 66th Annual Meeting and Exposition of the American Society of Hematology (ASH), which will take place from 7 to 10 ...

Mocravimod is being investigated in a global MO-TRANS Phase 3 study in patients with acute myeloid leukemia undergoing allogeneic hematopoietic ...

Takeda ( TSE:4502/NYSE:TAK ) today announced that it has entered into an exclusive licensing agreement with Keros Therapeutics, Inc. (Nasdaq: KROS) to further develop, manufacture and commercialize ...